Basel, 23 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile of these medicines.“Acute myeloid leukaemia remains a challenging blood cancer, with particularly low median survival rates in patients who cannot tolerate intensive chemotherapy given their age or underlying health,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Devel opment. “These data validate the benefit that this Venclexta/Venclyxto-based combination can bring to patients and we look forward to discussing the results with health authorities.” Data from the VIALE-A study will be shared with global health authorities and presented at an upcoming medical meeting. Venclexta has previously been granted accelerated approval by the US Food and Drug Administration (FDA) in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of people with newly-diagnosed…
CONCLUSIONS: Our study findings may aid in the development of behavioral interventions targeted to mitigate Black women breast cancer treatment disparities. We found modifiable factors (e.g. communication, satisfaction ratings) that support opportunities for clinicians to better address Black women’s needs regarding adjuvant treatment options. The development of tailored interventions for newly diagnosed Black breast cancer patients on patient related factors in health care are warranted for Black women with lower educational levels.
PMID: 32197898 [PubMed – as supplied by publisher]
The Arkansas Democrat-Gazette made a little history last week in covering a historic threat, the COVID-19 outbreak that has shut down normal social life in the United States and around the globe.
(Wiley) New research reveals rising rates of liver cancer around the world, despite advances aimed at preventing the disease. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS).
Context Therapeutics, a Philadelphia biopharmaceutical company focused on hormone-driven cancers, is teaming up with a Chinese biotech firm to advance the development of Context’s lead new drug candidate.
That experimental therapy, called onapristone ER, is being evaluated in mid-stage clinical testing in patients with certain types of ovarian and endometrial cancers.
Context plans to conduct mid-stage clinical testing of onapristone ER in patients with breast cancer later this year.
Multimorbidity is increasingly common and current healthcare strategies are not always aligned to treat this complex burden of disease. COPD, type-2 diabetes mellitus (T2D) and cardiovascular disease, especially atherosclerosis, occur more frequently together than expected, even when risk factors such as smoking, obesity, inactivity and poverty are considered. This supports the possibility of unifying mechanisms that contribute to the pathogenesis or progression of each condition.Neutrophilic inflammation is causally associated with COPD, and increasingly recognised in the pathogenesis of atherosclerosis …
Publication date: Available online 21 March 2020Source: Redox BiologyAuthor(s): Yuehong Wang, Junting Chen, Siwei Li, Xinying Zhang, Zuoming Guo, Jing Hu, Xiaoting Shao, Ningyang Song, Yajun Zhao, Hongzhu Li, Guangdong Yang, Changqing Xu, Can Wei
Publication date: 1 May 2020Source: Chemico-Biological Interactions, Volume 322Author(s): Lingzhi Chu, Joshua D. Wallach
European treatment trial launched; first confirmed case in Syria; Olympic committee considers ‘scaled-down’ Tokyo 2020. Follow the latest newsUK could face Italy-style lockdown, warns Boris JohnsonCoronavirus: at a glanceAustralia coronavirus – live updatesItaly shuts all non-essential businesses after 793 die in one daySee all of our coronavirus coverage12.41amGMTBritish musicians have already lost an estimated £13.9m (US$16m) in earningsbecause of coronavirus, according to a Musicians ’ Union survey.The organisation, which has 32,000 members and is the main trade union for the sector in the …
Publication date: Available online 21 March 2020Source: Clinical Epidemiology and Global HealthAuthor(s): Rekha Thapar, Ramesh Holla, Nithin Kumar, Shodhan Aithal, Sahana Karkera, Chaitra Rao, Nikhita Pujari, Ayshath Zahida, Bhaskaran Unnikrishnan, Prasanna Mithra, Darshan K. Swamy, Vaman Kulkarni, Darshan Bhagawan, Avinash Kumar
Publication date: Available online 21 March 2020Source: European UrologyAuthor(s): Keiichiro Mori, Shin Egawa, Shahrokh F. Shariat